Summit Therapeutics stock | 2026 earnings growth & current analysis

Summit Therapeutics

NasdaqGM:SMMT

$ 18,54

+ $0,23 (1,26%)

18,54 $

+$0,23 (1,26%)

Real-time: 12/08/2025 14:41

Summit Therapeutics Stock Value

Analysts currently rate NasdaqGM:SMMT as Buy.

Buy

Summit Therapeutics Company Info

EPS Growth 5Y

-12,77%

Market Cap

$14,12 B

Long-Term Debt

$0,10 B

Short Interest

9,18%

Annual earnings

02/25/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

2003

Industry

Health Care

Country

United States

ISIN Number

US86627T1088

Website

http://www.smmttx.com

Analyst Price Target

$35,42

93.45%

Last Update: 12/08/2025

Analysts: 13

Highest Price Target $42,50

Average Price Target $35,42

Lowest Price Target $12,08

In the last five quarters, Summit Therapeutics’s Price Target has risen from $14,68 to $33,65 - a 129,22% increase. Eleven analysts predict that Summit Therapeutics’s share price will increase in the coming year, reaching $35,42. This would represent an increase of 93,45%.

Top growth stocks in the health care sector (5Y.)

What does Summit Therapeutics do?

Summit Therapeutics Inc. (Summit) operates as a biopharmaceutical company. The company focuses on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company’s pipeline of product candidates is designed with the intention to become the patient-friendly, new-era standard-of-care medicines, in the therape...

Summit Therapeutics Inc. (Summit) operates as a biopharmaceutical company.

The company focuses on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company’s pipeline of product candidates is designed with the intention to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.

The company’s lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the company entered into a Collaboration and License Agreement (the ‘License Agreement’) with Akeso, Inc. and its affiliates (collectively, ‘Akeso’) pursuant to which the company has in-licensed intellectual property related to ivonescimab. Through the License Agreement, the company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan. On June 3, 2024, the company entered into an amendment to the License Agreement with Akeso to expand its territories covered under the License Agreement to also include the Latin America, the Middle East and Africa regions (collectively, and as expanded, the ‘Licensed Territory’). The company’s operations are focused on the development of ivonescimab and other future activities, as it determines.

The company has begun its development for ivonescimab in non-small cell lung cancer (‘NSCLC’), specifically launching Phase III clinical trials in the following proposed indications:

ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (‘EGFR’)-mutated, locally advanced or metastatic non-squamous NSCLC who has progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (‘TKI’) (‘HARMONi’); and

ivonescimab combined with chemotherapy in first-line metastatic NSCLC patient s (‘HARMONi-3’).

In addition, the company has begun to activate clinical trial sites in the United States for a Phase III clinical study in the following proposed indication:

ivonescimab monotherapy in first-line metastatic NSCLC patients with high PD-L1 expression (‘HARMONi-7’).

In October 2024, the company completed enrollment in its HARMONi clinical trial. The company expects to disclose topline results from HARMONi in mid-2025, depending upon maturation of the data per the protocol.

Akeso Collaboration and License Agreement

Pursuant to the License Agreement with Akeso, the company received the rights to develop and commercialize ivonescimab in the Licensed Territory. Akeso will retain development and commercialization rights for the rest of the world excluding the Licensed Territory.

Furthermore, on June 3, 2024, the company entered into an amendment to the License Agreement with Akeso to expand its territories covered under the License Agreement to also include the Latin America, Middle East and Africa regions.

Ivonescimab

Ivonescimab is a novel potential first-in-class PD-1 / VEGF bispecific antibody, believed to be the most advanced in clinical development in the Licensed Territory. Engineered with Akeso’s unique Tetrabody technology, ivonescimab, as a single molecule, blocks programmed cell death protein 1 (‘PD-1’) from binding to PD-L1 and PD-L2, and blocks vascular endothelial growth factor (‘VEGF’) from binding to VEGF receptors. Ivonescimab is designed to potentially allow cooperative binding of the intended targets, such that the binding of PD-1 increases the binding affinity of VEGF. In view of the co-expression of VEGF and PD-1 in the tumor micro-environment (‘TME’), ivonescimab may block these two pathways more effectively and enhance the antitumor activity, as compared to combination therapy through what is believed to be a unique cooperative binding mechanism.

Ivonescimab is being developed by both Akeso and the company in multiple Phase III clinical trials. There are also multiple early-phase trials being conducted in multiple solid tumors. Ivonescimab has been dosed in more than 2,300 patients globally.

Akeso-Sponsored Ivonescimab Trials

Akeso is developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is currently approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial that was first announced and presented in 2024. In addition, a supplemental application has been submitted in China by Akeso for ivonescimab as monotherapy based on the results of the HARMONi-2 study in first-line, PD-L1 positive non-small cell lung cancer. Further details related to these two trials, in addition to other Phase II clinical data presented during 2024, are described further below. In addition, Akeso is conducting Phase III clinical trials in combination with chemotherapy in first-line advanced squamous NSCLC (HARMONi-6) and first-line biliary tract cancer (HARMONi-GI1), as well as in combination with ligufalimab, a proprietary Akeso-owned investigational CD-47 monoclonal antibody, in first-line recurrent / metastatic PD-L1 positive head-and-neck cancer (HARMONi-HN1). Further, Akeso has announced its intention to conduct Phase III clinical trials in combination with chemotherapy in first-line advanced PD-L1 low or negative triple-negative breast cancer (HARMONi-BC1) and first-line advanced pancreatic cancer (HARMONi-GI2).

HARMONi-A

Based on data published by Akeso at the American Society of Clinical Oncology (ASCO 2024) and in a recent publication in the Journal of the American Medical Association (JAMA) in the HARMONi-A study, in a single-region (China), randomized, double-blinded Phase III study in patients with NSCLC who have progressed following an EGFR-TKI, ivonescimab achieved its primary endpoint of PFS when combined with doublet chemotherapy (pemetrexed and carboplatin). Patients experienced a 54% reduction in disease progression or death as compared to placebo plus doublet-chemotherapy (HR: 0.46, 95% CI: 0.34 - 0.62; p<0.001). In a pre-specified subgroup analysis of patients who received a previous third-generation TKI, a hazard ratio of 0.48 was observed. A median Overall Survival (mOS) in this study of 17.1 months was observed, reflecting a 20% reduction in death as compared to placebo plus chemotherapy in the study (HR: 0.80, 95% CI: 0.59 - 1.08). The Phase III study was considered to have demonstrated a tolerable safety profile and a low discontinuation rate for adverse events.

HARMONi-2

After announcing positive qualitative results for the HARMONi-2 trial, also referred to as AK112-303, a randomized, single-region (China) Phase III study sponsored by Akeso, on May 30, 2024, the company announced, on September 8, 2024, quantitative data from the primary analysis of the Phase III HARMONi-2 trial featuring ivonescimab that was presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2024 World Conference on Lung Cancer (WCLC 2024). The HARMONi-2 presentation evaluated monotherapy ivonescimab compared to monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression. HARMONi-2 is a single region, multi-center, double-blinded Phase III study conducted in China sponsored by Akeso, with data generated and analyzed by Akeso.

In the HARMONi-2 primary analysis, ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, PFS by Independent Radiologic Review Committee (IRRC), when compared to monotherapy pembrolizumab, achieving a hazard ratio of 0.51 (95% CI: 0.38, 0.69; p<0.0001). A clinically meaningful benefit was demonstrated across clinical subgroups, including patients with tumors with high PD-L1 expression. Overall survival data was not yet mature at the time of the data cutoff and will be evaluated in the future.

Ivonescimab demonstrated an acceptable and manageable safety profile, which was consistent with previous studies. There were three patients (1.5%) who discontinued ivonescimab due to treatment-related adverse events (‘TRAEs’) compared to six patients (3.0%) who discontinued pembrolizumab due to TRAEs. There was one patient in the ivonescimab arm and two patients in the pembrolizumab arm who died as a result of TRAEs in this Phase III study.

Additional Phase II Data Sets

In addition to the HARMONi-2 data announced at WCLC 2024, Akeso also announced Phase II trial results from AK112-205, for patients with Stage II or III resectable NSCLC. Further, the company announced data for ivonescimab was presented as a part of the 2024 European Society for Medical Oncology Annual Meeting (ESMO 2024) featuring updated Phase II ivonescimab data in advanced triple-negative breast cancer (TNBC), recurrent / metastatic head and neck squamous cell carcinoma (HNSCC), and metastatic microsatellite-stable (MSS) colorectal cancer (CRC). At ASCO 2024, Akeso presented ivonescimab Phase II data in biliary-tract cancer (BTC). Earlier, at the 2024 European Lung Cancer Conference (ELCC 2024), Akeso announced updated data from AK112-201 (Cohort 1), a Phase II study for patients with first-line advanced NSCLC. Each trial from which the data was generated was a multi-center Phase II study conducted in China sponsored by Akeso, with data generated and analyzed by Akeso.

Product Pipeline

Summit Sponsored Ivonescimab Trials

Ivonescimab is being investigated in global Phase III clinical trials. Phase I and II trials were completed by or are ongoing with the company’s partner Akeso. This pipeline reflects Phase III clinical trials that has been or are planned to be initiated by Summit in its Licensed Territory.

HARMONi study (NCT05184712) is a Phase III, multi-regional, potentially registration-enabling clinical trial, which enrolled patients in North America, Europe, and China. Patients enrolled in China were also enrolled as a part of the HARMONi-A study. The company completed the enrollment of patients in North America and Europe in October 2024. The two primary endpoints for this study are progression-free survival (‘PFS’) and overall survival (‘OS’), and the study compares ivonescimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy in patients with advanced or metastatic EGFR-mutated NSCLC whose tumors has progressed following treatment with a third generation EGFR-TKI. The company expects to disclose top-line results from HARMONi in mid-2025, depending upon maturation of the data per the protocol.

The U.S. Food and Drug Administration (‘FDA’) has granted Fast Track designation for the proposed use of ivonescimab in combination with platinum-based chemotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR mutation, who have experienced disease progression following EGFR-TKI therapy.

HARMONi-3 study (NCT05899608) is a Phase III, multi-regional, potentially registration-enabling clinical trial for which the company initiated activating sites in North America and China during the fourth quarter of 2023 and later in Europe in 2024. The two primary endpoints for this study are PFS and OS, and the study compares ivonescimab plus platinum-based doublet chemotherapy versus pembrolizumab plus platinum-based doublet chemotherapy in first-line patients with metastatic squamous NSCLC, and based on changes made to the protocol in the fourth quarter of 2024, non-squamous NSCLC. Enrollment is ongoing in all regions for patients with squamous tumors; the protocol amendment is effective, and enrollment has begun in United States in the fourth quarter of 2024 for patients with non-squamous tumors. The company plans to enroll an estimated 1,080 patients.

Based on the results of HARMONi-2, the company has begun to activate clinical trial sites in the United States for HARMONi-7. HARMONi-7 is a multi-regional Phase III clinical trial that will compare ivonescimab monotherapy to pembrolizumab monotherapy in patients with metastatic squamous and non-squamous NSCLC whose tumors have high PD-L1 expression. The sample size for this study is planned to have an estimated 780 patients with two primary endpoints, PFS and OS.

Summit is conducting its current clinical trials, and plans to design and conduct additional clinical trial activities for ivonescimab within its Licensed Territory, to support and submit relevant regulatory filings. The company intend to explore further clinical development of ivonescimab in solid tumor settings outside of metastatic non-small cell lung cancer, the company’s current area of focus in its Phase III clinical trials.

In the fourth quarter of 2023, the company began collaborating with multiple institutions globally and opened the company’s investigator-sponsored trials program across several disease areas. The company continued to expand this program in 2024 in order to discover additional opportunities for ivonescimab, including in several tumors outside of the company’s current development plan.

The company plans to review the data generated from these clinical trials as a part of the company’s consideration for advancing the company’s clinical development pipeline for ivonescimab in the Licensed Territory.

Government Regulation

As a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for serious diseases, the company is subject to extensive and ongoing regulation by government authorities, including regulation by the United States Food and Drug Administration (‘FDA’) under the Federal Food, Drug, and Cosmetic Act (‘FDCA’) and its implementing regulations, as well as by other regulatory bodies in the United States, Europe and other countries in which it operates.

The company is subject to or affected by numerous data privacy and security obligations, that apply in Europe and other countries, including the European Economic Area’s (EEA’s) General Data Protection Regulation (‘GDPR’).

History

Summit Therapeutics Inc. was founded in 2003. The company was incorporated in Delaware in 2020.

Summit Therapeutics Questions and Answers

Which sectors generate sales and which are the top 3 markets?

Industry Revenue Breakdown: Pharmaceutical Research and Development: 100% (2025) TOP 3 Markets: USA: 60% Europe: 25% Asia: 15% Summit Therapeutics Inc. generates its revenue mainly from pharmaceutical research and development, with a focus on developing new antibiotics and therapies. T...

At which locations are the company’s products manufactured?

Production Sites: No specific current data available (as of 2025) Summit Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for the treatment of infectious diseases and rare genetic disorders. In the past, the company has frequently outsourced its production processes t...

What strategy does Summit Therapeutics pursue for future growth?

Strategic Partnerships: Collaboration with Akeso, Inc. (2023) Focus on Oncology: Expansion of the pipeline in cancer treatment Summit Therapeutics Inc. pursues a growth strategy that heavily relies on strategic partnerships and expanding its product pipeline in the field of oncology. In 2023, the co...

Which raw materials are imported and from which countries?

Main raw materials: Pharmaceutical active ingredients, chemicals for research and development Countries of origin: USA, China, India (estimated) Summit Therapeutics Inc. is a biopharmaceutical company that focuses on the development of new drugs. The main raw materials imported by the company are ph...

How strong is the company’s competitive advantage?

Market share in the field of antibiotics: 8% (2024, estimated) R&D expenses: $120 million (2024) Patent portfolio: 15 active patents (2025) Summit Therapeutics Inc. has established itself as a significant player in the field of antibiotic development in recent years. The company's competitive ad...

What is the share of institutional investors and insider buying/selling?

Institutional Investor Share: 35% (2025, estimated) Insider Purchases: 500,000 shares (2025, estimated) Insider Sales: 200,000 shares (2025, estimated) The institutional investor share in Summit Therapeutics Inc. is estimated to be around 35%. This indicates a moderate level of confidence from insti...

What percentage market share does Summit Therapeutics have?

Market share of Summit Therapeutics Inc.: Estimate < 1% (2025) Top competitors and their market shares: Pfizer Inc. - approx. 10% (2025) Roche Holding AG - approx. 9% (2025) Novartis AG - approx. 8% (2025) Merck & Co., Inc. - approx. 7% (2025) Johnson & Johnson - approx. 6% (2025) GlaxoS...

Is Summit Therapeutics stock currently a good investment?

Revenue Growth: 20% (2024) Research and Development Expenses: 35% of revenue (2024) Partnerships: Collaboration with leading pharmaceutical companies (2024) Summit Therapeutics Inc. achieved an impressive revenue growth of 20% in 2024. This indicates strong demand for their products and services. A...

Does Summit Therapeutics pay a dividend – and how reliable is the payout?

Dividend payment: None (2025) Summit Therapeutics Inc. currently does not pay a dividend. The company focuses on the development and commercialization of new therapies, particularly in the field of antibiotics. In the biotechnology industry, it is common for companies in the development phase not to...

Summit Therapeutics Stock Value

Summit Therapeutics Company Info

Analyst Price Target

Top growth stocks in the health care sector (5Y.)

What does Summit Therapeutics do?

Summit Therapeutics Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal